AbD Serotec, a Division of MorphoSys, is dedicated to providing high-quality reagents and technical expertise to scientists researching all aspects of neuroscience, including axonal guidance, neural development and demyelination disorders. To support these three key focus areas, AbD Serotec has produced a new series of complimentary reference posters.
The study of axonal guidance and growth is a specialist discipline in developmental biology. Correct wiring of the nervous system depends on the ability of axons to be guided by repulsive and attractive cues to their correct destination. To assist researchers in their quest to decipher the mechanisms of axonal guidance, AbD Serotec provides key investigative tools including a unique antibody to 2G13P localized on growth cones, plus antibodies to Ephrins, Vimentin and other key targets.
Neural Stem Cells (NSCs) and glial cells are also important in the development of the nervous system. Cell fate mapping is a relatively new area and there are a number of significant specificities such as GFAP, Myelin Basic Protein and CD11b for identifying the numerous types of cells across the glial cell lineage.
In addition, AbD Serotec specializes in markers for oligodendrocytes, a type of glial cell found in the central nervous system responsible for myelination. Specificities include phosphorylated Myelin Basic Protein and Galactocerebroside. Damage to oligodendrocytes can be a consequence of demyelination disorders such as multiple sclerosis. These neuroscience posters are educational and serve as great research aids by listing all the antibody markers available for each of the three focus areas described above. They may be downloaded from the website at www.abdserotec.com or may be requested from Victoria Warltier, Market Segment Manager, Tel: +44 1865 852 768; Email: Victoria.Warltier@abdserotec.com.
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCAL®) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), Daiichi Sankyo & Co., Ltd. (Tokyo/Japan), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Merck & Co., Inc. (Whitehouse Station, New Jersey/USA), Novartis AG (Basel, Switzerland), Novoplant GmbH (Gatersleben, Germany), OncoMed Pharmaceuticals Inc. (Mountain View, C USA), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany), Schering-Plough (Palo Alto/USA), Shionogi & Co., Ltd. (Osaka/Japan), Xoma Ltd. (Berkeley, California/USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit.